What the FDA labels say about taking them together
Carbamazepine and oliceridine
Oliceridine's FDA label of December 31, 2025 names carbamazepine in its drug interactions section; the carbamazepine labels PlainMeds reads (3) do not name oliceridine. The oliceridine label: “The concomitant use of OLINVYK and CYP3A4 inducers can decrease the plasma concentration of oliceridine, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical …”
Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the oliceridine FDA label on DailyMed (effective December 31, 2025, Trevena, Inc.).
What does the carbamazepine label say about oliceridine?
Carbamazepine's label (effective August 20, 2026) and its 2 other brand-application labels do not name oliceridine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed
What does the oliceridine label say about carbamazepine?
Oliceridine label, drug interactionsInducers of CYP3A4 Clinical Impact: The concomitant use of OLINVYK and CYP3A4 inducers can decrease the plasma concentration of oliceridine, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to oliceridine.. … consider OLINVYK dosage reduction and monitor for signs of respiratory depression. Examples: Rifampin, carbamazepine, phenytoin
Source: FDA drug label (OLINVYK), Trevena, Inc., effective December 31, 2025 (SPL set ce167984-8b9d-40b7-84ce-d0f33fff1eaa), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Carbamazepine | Oliceridine | |
|---|---|---|
| Labeled for | Bipolar disorder, Seizures and epilepsy | Pain |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.119 per tablet 200 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once